Short- and long-term complications after slowly resorbable biosynthetic P4HB mesh (Phasix) implantation in European centres: a protocol paper for a multiregistry study Authors: Rudolf van den Berg, Marie Wieser, Johannes Jeekel, Cesare Stabilini, José Bueno-Lledó, Ferdinand Köckerling, Grigorios Chatzimavroudis, Lars Nannestad Jørgensen, Benoit Romain, PRS Group (Phasix Research Study Group) Published: 2025 ABSTRACT Abstract ABSTRACTBackgroundPhasix mesh is a fully resorbable synthetic mesh for use in clean and contaminated ventral incisional hernia repairs. Long-term absorbable Phasix mesh appears to be a safe and promising device in incisional hernia repair, with low recurrence rates; however, data on long-term complications after surgery, particularly after the resorption period of the mesh, are scarce.Methods and analysisThis protocol describes a study of several European registries on the use of a Phasix mesh in incisional hernia repair. The primary endpoint of the study is long-term complications at 2–5 year follow-up after mesh implantation, with secondary endpoints including hernia recurrence and complications during short-term follow-up.Ethics and disseminationEthical approval was not required for this protocol as the study is based on anonymised registry data collected with prior patient consent in each registry. Each participating registry has its own ethical approval process, and this study will adhere to those regulations. The results will be disseminated through peer-reviewed publications and conference presentations.Keywords: Adult surgery; Colorectal surgery; Hospitals, Public STRENGTHS AND LIMITATIONS OF THIS STUDY Multiregistry, multinational design ensures a large and diverse patient population, increasing generalisability across European healthcare systems. Multiregistry, multinational design ensures a large and diverse patient population, increasing generalisability across European healthcare systems. Use of prospectively maintained registries enhances data reliability and reduces recall bias compared with retrospective chart reviews. Use of prospectively maintained registries enhances data reliability and reduces recall bias compared with retrospective chart reviews. Standardised definitions of complications and outcomes (based on European Hernia Society and Clavien–Dindo classifications) improve comparability across centres. Standardised definitions of complications and outcomes (based on European Hernia Society and Clavien–Dindo classifications) improve comparability across centres. Heterogeneity between registries in follow-up duration, outcome and risk factor definition, and data completeness may introduce variability in long-term outcome assessment. Heterogeneity between registries in follow-up duration, outcome and risk factor definition, and data completeness may introduce variability in long-term outcome assessment. Potential for missing data and loss to follow-up is mitigated by registry-based tracking but remains a methodological limitation. Potential for missing data and loss to follow-up is mitigated by registry-based tracking but remains a methodological limitation. Introduction Phasix mesh is a fully resorbable synthetic mesh implant prepared from poly-4-hydroxybutyrate (P4HB). P4HB is produced from a naturally occurring monomer, which is processed into monofilament fibres and then knitted into a surgical mesh. Phasix mesh degrades through a process of hydrolysis and a hydrolytic enzymatic digestion. The absorption process of Phasix takes 12–18 months and recurrence after this period is a major concern.1 2 Previous studies have demonstrated the safety and short-term efficacy of Phasix mesh in both clean and contaminated surgical fields.3 4 As a result, long-term recurrence has been studied in various studies, ranging from a recurrence rate of 5.7%–22.2% with a follow-up of more than 18 months, for all Ventral Hernia Working Group (VHWGs) combined.5,16 Focused on long-term follow-up, a recent meta-analysis including 1858 patients operated on for ventral hernia with a maximal median follow-up of 62.3 months demonstrated a recurrence rate of 9%, confirmed in the sub-meta-analysis restricted to studies with follow-up of more than 18 months.14 A higher recurrence rate, as expected in the VHWG15 II and III, was demonstrated in the study of Bueno-Lledo et al with an overall recurrence rate after Phasix mesh hernia repair of 14.4% of 236 patients after 41 months follow-up.16 Another study of 84 patients with VHWG grade III incisional midline hernia reported a recurrence rate of 15.9% after 60 months follow-up.17 These results concerning rates of recurrence are consistent with long-term recurrence reported with synthetic mesh.18 19 Concerning mesh-related complications, the majority of them seem to occur primarily in the first year and much less after two or more years after mesh resorption.8 A recent meta-analysis by Tran et al showed a 35% rate of any complications and 10% surgical site infection (SSI) of the 1858 patients followed during 62.3 months.15 Furthermore, the study of Bueno-Lledo et al demonstrated an overall rate of surgical site occurrence (SSO) of 30% and SSI of 8.4% in VHWG grades II and III combined.16 A SSO rate of 28.7% and SSI rate of 11.2% were described in a VHWG grade III subgroup, which were the most represented cases in this study and showed acceptable results in contaminated fields.16 A recent systematic review and meta-analysis of six studies including 472 patients compared the use of P4HB biosynthetic mesh in 391 clean and 81 contaminated ventral incisional hernia repairs (IHRs). The overall pooled incidence of SSO was 18% with 14% in clean cases versus 35% in contaminated cases combined to an overall pooled incidence of hernia recurrence of 6%.20 These observations were strengthened in the study of Van den Dop et al with a follow-up of 60 months in VHWG grade III patients that showed a SSO rate of 37.7% with 11.5% of patients developing a SSI, which compare favourably to the SSI reported for synthetic and biologic meshes.21 Slowly absorbable Phasix mesh appears to be a safe and promising device for IHR, with low long-term recurrence rates, indicating tissue reconstruction of the abdominal wall did take place. This reconstruction apparently strengthens the abdominal wall in such a way that recurrence rates are relatively low after 2 years, when the mesh has been completely resorbed. In one study, there were no mesh complications after 2 years, no mesh pain, no mesh infection and no mesh explantation.17 These complications occur frequently with synthetic mesh repair: 4.5%–12% surgery for mesh complications, 4%–12% mesh explantation for mesh infection and 1% mesh explantation for pain.22 23 However, studies investigating long-term slowly resorbable biosynthetic mesh complications and behaviour after 2 years are scarce, due to the relatively small number of participants and a large loss to follow-up. The aim of this multiregistry study of European databases is to analyse the occurrence of postoperative mesh-related complications with a long-term follow-up beyond the resorption time of the biosynthetic mesh. The primary endpoint will be long-term complications at 2–5 year follow-up after mesh resorption, and secondary endpoints are hernia recurrence and complications during short-term follow-up. The aim of this study is to present the results of slowly resorbable mesh and to facilitate comparison to the literature on synthetic prostheses. Methods Study design A retrospective descriptive study of prospective registry-based data will be performed including several European registries (France, Greece, Denmark, Germany, Italy, Portugal and Spain). The centres include their consecutive patients who underwent IHR with the use of a P4HB mesh from the start of the registries till July 2024. Hernia repair was either performed with a Phasix mesh (generally placed in an onlay or retromuscular location) or a Phasix ST mesh (generally placed in an intraperitoneal location). Regarding the degree of contamination of the surgical field, patients will be categorised using the VHWG classification.15 VHWG grade I refers to the ‘low risk’ group of complications and no history of wound infection; VHWG grade II refers to the ‘comorbid’ group (those with obesity, diabetes, history of smoking, chronic obstructive pulmonary disease); VHWG grade III refers to a potentially contaminated group with previous wound infection, a stoma or a concomitant gastrointestinal procedure. VHWG grade IV represents a contaminated dirty wound area. Patients will be grouped into two groups according to the VHWG classification: VHWG grades I–II, and VHWG grades III–IV. The primary endpoint is to study long-term complications arising between 2 years and 5 years after mesh implantation. The lower limit of 2 years corresponds to the theoretical resorption time of the biosynthetic mesh. Complications are defined as SSI and SSO, including chronic pain and surgery for mesh complications (enterocutaneous fistulas, mesh infection), mesh explantation for pain or for infection. Participants Male and female adult (18 years or older) patients with a confirmed diagnosis of a ventral incisional hernia will be eligible for inclusion into the study. Participants are required to have been included in a registry and have given consent for the use of their data. Patients with any VHWG grade will be eligible for inclusion. Patients who, in the absence of an abdominal wall hernia, received a prophylactic Phasix mesh are excluded. Furthermore, patients who underwent stomy site closure or diastasis recti repair using a Phasix mesh are excluded. Data collection Demographic, preoperative and operative characteristics were recorded based on clinical files in the registries. These characteristics include age, sex, body mass index, previous comorbidities and risk factors (smoking, obesity, hypertension, diabetes, history of wound infection and hernia repair at the same site, immunosuppression due to cancer or treatments, American Society of Anesthesiologists (ASA) score, VHWG scores, mesh size, size of the hernia, number of previous attempted repairs, location of the mesh, fixation of the mesh and drainage. Indications for the use of biosynthetic absorbable mesh were also described. Further data on concomitant procedures such as bowel resections will be collected and presented. The size of the mesh, the precise method of repair and mesh fixation techniques were recorded. Recurrences are defined according to the definition of the European Hernia Society: ‘any abdominal wall gap with or without bulge in the area of a postoperative scar perceptible or palpable by clinical examination or imaging’. A recurrence is diagnosed on physical examination by an experienced surgeon or abdominal ultrasonography or abdominal CT. In case of observed discrepancies between the physical examination and imaging, the CT findings are decisive. Patient-reported presence of an abdominal wall hernia will be analysed separately from the recurrences as defined by the European Hernia Society. Outcomes The primary endpoint of the study is the occurrence of long-term complications at 2–5 year follow-up after mesh resorption. The following postoperative complications include general complications and specific complications at the operative site, which will be recorded: SSI and SSO, and chronic pain and surgery for mesh complications (enterocutaneous fistulas, mesh infection), mesh explantation for pain or for infection. SSI is defined by superficial and deep infections24 and SSO is defined by cellulitis, SSI, seroma, haematoma, enteral fistula, infected mesh or wound disunion. Complications are graded according to the Dindo-Clavien classification.25 A complication≥grade III is considered major, and ≤grade II considered minor. Secondarily, other complications including hernia recurrence and complications during short-term follow-up will be assessed. The follow-up used in the registries will be the basis for data collection and thus varies between registries. Efforts will be made to overlay these differing follow-ups. A dictionary for complication definition was made and is provided in table 1. Table 1Definition of the different complicationsWound complicationDefinitionSSOEvents occurring within 90 days of hernia repair. SeromaCollection of serous fluid in abdominal wall that is either symptomatic (causes pain/discomfort) or requires intervention. HaematomaCollection of blood in the abdominal wall that is either symptomatic (causes pain/discomfort) or requires intervention. Soft tissue breakdownSkin and/or adipose tissue breakdown requiring debridement or packing. Does not include fascial dehiscence. Fascial dehiscenceFascial separation without evidence of infection or inflammation requiring clinical intervention. CellulitisErythema of skin or subcutaneous connective tissue that does not involve the surgical site but requires treatment with antibiotics. Suture granulomaLocalised inflammatory reaction in response to retained suture material requiring intervention, without evidence of infection. Chronic draining sinusSinus tract in abdominal wall draining serous or fibrinous fluid without evidence of gross purulence. Enterocutaneous fistulaConnection from the gastrointestinal tract to the skin with spillage of enteric contents.SSIInstances of infection occurring within 90 days of hernia repair or up to 1 year for deep and organ/space SSIs with presence of implant.Superficial SSIInfection involving skin or subcutaneous tissue along with ≥1 of the following: purulent drainage, organisms isolated from fluid/tissue, one sign of inflammation (pain/tenderness, induration, erythema, local warmth), deliberate wound opening by surgeon.Deep SSIInfection involving deep soft tissues (fascia and/or muscle) with ≥1 of the following: purulent drainage, fascial dehiscence with signs of inflammation, deliberate fascial separation by surgeon, deep abscess identified by direct examination, reoperation or radiologic verification or surgeon declaration.Organ/space SSIInfection involving anatomic structures not opened or manipulated by operation or peritoneal cavity with ≥1 of the following: purulent drainage from drain or incision into organ/space, organisms isolated by aseptic culture, identification of abscess by direct identification, reoperation or radiologic verification.SSI, surgical site infection; SSO, surgical site occurrence. Definition of the different complications SSI, surgical site infection; SSO, surgical site occurrence. Data management and data safety monitoring Data will be collected from anonymised registries. Therefore, the handling of personal data will comply with the EU General Data Protection Regulation and any local regulations. A common database will be constructed for the pooling of the different patients from the various registries. All baseline characteristics, operation characteristics and the various outcomes will be included in the database. An additional variable will be added to identify the registry in which the patient was originally included. After completion of the data sets by the various registries, transfer of the data sets will be conducted via an encrypted and secured data transfer. The data sets from the various registries will then be combined in the Erasmus MC where they will securely be stored. All statistical analysis will be conducted using RStudio. Statistical analysis Qualitative variables will be described as percentages and compared with a χ2 test or Fisher’s exact test as appropriate. Quantitative variables will be described with their mean and SD and/or as a median and IQR. Student’s t test will be used to compare means of continuous variables if they are normally distributed, and the Mann–Whitney-Wilcoxon test will be used if they are not. Normality will be assessed visually using Q–Q plots. The threshold of significance will be set at p<0.05. A Kaplan–Meier survival analysis will be performed to study the various complications, potentially complementary to a Cox-regression model if the proportional hazards assumption holds. Hereby accounting for the differing follow-up times in the registries by a censored analysis. Variables having a p<0.20 in the univariate analysis were retained for the multivariate analysis. A centre effect will be assessed by comparing two models: one with the centre as an explanatory variable and the other without the centre (positive if p<0.05). Missing data In case of many missing data points (defined as over >10% of cases), we will consider using multiple imputation techniques such as ‘Multivariate Imputation by Chained Equations’ to impute the missing data, keeping the levels of clustering in regard. Data analysis will then be computed on each data set individually and results will be pooled using Robbins’ rules. Discussion Biosynthetic resorbable meshes have recently been developed to address disadvantages of biological and synthetic meshes. One of these is the biosynthetic P4HB Phasix mesh, which is resorbed after 12–18 months, hypothetically providing the right timing and speed of resorption for the abdominal wall to reconstruct. Infection susceptibility and long-term mesh complications are, after resorption, supposedly decreased when compared with permanent synthetic meshes. Recurrence after mesh resorption has been a major concern.1 However, recent studies showed relatively low long-term recurrence rates as cited before.6,21 While research has focused on postoperative recurrence of an incisional hernia in patients operated for an incisional hernia using a Phasix resorbable mesh and showed acceptable recurrence rates, few data are present on the occurrence of postoperative complications after the resorption period of the mesh. This study will combine data across various registries around Europe to give a comprehensive representation of the possible advantages and drawbacks of using Phasix resorbable mesh. The study is a collaborative initiative from registries on ventral hernia repair surgery throughout Europe. By combining data from their large registries, a sample size surpassing that of already published articles on resorbable mesh placement for IHR can be obtained. This initiative provides more evidence than regular retrospective studies conducted in single centres. The originality of this project lies in its primary objective of identifying long-term complications rather than merely recurrences, with the hypothesis that the incidence of long-term complications will be less than the incidence with synthetic meshes as described in the literature. Due to a use in surgical fields with different contamination grades, Phasix meshes are difficult to compare to synthetic meshes; this study will provide indirect arguments to clarify their indications. A significant strength of the study is its unique position in the literature, as few articles have addressed this topic with such a long follow-up period on a cohort of individuals with an adequate sample size. However, a potential weakness is the risk of loss to follow-up over time. This concern is mitigated by the fact that the patients are often selected from prospective collections in national registries, which helps ensure comprehensive tracking and data integrity. The different follow-up durations of the registries will introduce a loss to follow-up for assessing long-term complications, which will be accounted for with Kaplan-Meier models accounting for censoring. The assessment of these complications on long-term might therefore be less certain than on the short term but will still provide a good estimation of the true complication levels. The hypothesis is that this study will demonstrate the superiority of the Phasix mesh in (contaminated) ventral hernia repair surgery, compared with synthetic meshes, by showing lower incidence of long-term complications with comparable recurrence rates. Results for synthetic prostheses will be based on a review of the literature, although this could prove difficult due to differences in risk factors and outcomes for the populations studied. Ethics and dissemination Informed consent is obtained at enrolment into each registry by its members. Because this study uses only anonymised, previously collected registry data, additional ethical approval was not required. Each participating registry obtained its own approval in accordance with national regulations. All data are anonymised prior to transfer, in compliance with the EU General Data Protection Regulation. The investigators are committed to disseminating the findings through peer-reviewed journals and international scientific meetings, following STrengthening the Reporting of Observational Studies in Epidemiology guidelines. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Prepublication history for this paper is available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2024-098099). Patient consent for publication: Not applicable. Provenance and peer review: Not commissioned; externally peer reviewed. Collaborators: PRS Group (Phasix Research Study Group): Giorgio Soliani, Manuel López-Cano, Jose Antonio Pereira Rodriguez, Jean-François Gillion, Vincent Dubuisson, Pablo Ortega-Deballon, Niki Christou, Yohann Renard, David Moszkowicz, Guillaume Péré, Gregory Baud, Guillaume Passot, Benjamin Barrat, Constanza Gonella-Pacchiotti. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research. Contributor Information PRS Group (Phasix Research Study Group): Giorgio Soliani, Manuel López-Cano, Jose-Antonio Pereira Rodriguez, Jean-François Gillion, Vincent Dubuisson, Pablo Ortega-Deballon, Niki Christou, Yohann Renard, David Moszkowicz, Guillaume Péré, Gregory Baud, Guillaume Passot, Benjamin Barrat, and Constanza Gonella-Pacchiotti References